Cybin Inc. Transfers to Nasdaq, Changes Ticker to HELP
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 18 2025
0mins
Source: Businesswire
- Market Transition: Cybin Inc. announced its voluntary transfer from NYSE American to Nasdaq effective January 5, 2026, marking a significant step in the company's evolution within the global pharmaceutical sector, which is expected to enhance market recognition and investor confidence.
- Brand Revitalization: Upon listing on Nasdaq, the company will operate under the name Helus Pharma, aiming to better reflect its commitment to innovation in mental healthcare, thereby attracting increased attention and investment.
- Liquidity Enhancement: The move to Nasdaq is anticipated to improve the liquidity of Cybin's shares, as Nasdaq has a broader investor base, potentially providing more opportunities for future financing and expansion.
- R&D Progress: With CYB003 and CYB004 in Phase 3 and Phase 2 clinical trials respectively, the transition to Nasdaq will help elevate the visibility of Cybin's R&D projects, attracting potential partners and investors to support its innovative drug development efforts.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like CYBN with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on CYBN
Wall Street analysts forecast CYBN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CYBN is 45.00 USD with a low forecast of 30.00 USD and a high forecast of 55.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 8.280
Low
30.00
Averages
45.00
High
55.00
Current: 8.280
Low
30.00
Averages
45.00
High
55.00
About CYBN
Cybin Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company creates psychedelic-based therapeutics to address the unmet need for treatment options for people who suffer from mental health conditions. Its N, N-dimethyltryptamine (DMT) and dDMT programs create a dataset of systematic research on these psychedelic molecules. The Company is developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder, and CYB004, a proprietary deuterated dDMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. CYB003 moves to Phase III and CYB004 moves to Phase II.CYB005 is in Preclinical stage. It has an intellectual property portfolio in the psychedelic drug development sector with over 80 patents granted and over 230 patent applications pending. The Company operates in Canada, the United States, the United Kingdom, the Netherlands, and Ireland.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Organigram Expands Investment in Phylos to $10 Million for Cannabis Genetics
- Strategic Investment Expansion: Organigram Global Inc. has increased its investment in Phylos Bioscience from $7 million to $10 million, aiming to enhance its leadership in seed-based cannabis cultivation by securing priority access to advanced genetics and a robust seed pipeline, which is expected to strengthen its competitive position in both medical and recreational cannabis markets.
- Loan Agreement Revision: The investment includes a revised loan agreement with an additional $3 million advance, maturing on May 25, 2028, ensuring Organigram's exclusivity for selected autoflower cultivars over the next five years, further solidifying its market position.
- Market Share Growth: Through its partnership with Phylos, Organigram plans to scale seed-based production by 2030, which is anticipated to significantly enhance product consistency and economic benefits, thereby meeting the increasing consumer demand.
- Technology-Driven Advantage: Organigram began utilizing seed-based production technology in 2023, marking a transformation in its operational model, which is expected to yield long-term economic benefits and competitive advantages in the market.
Continue Reading
Cybin Inc Launches $100 Million Equity Program, Shares Drop 6.6%
- Stock Decline: Cybin Inc's shares fell 6.6% to $8.00 in pre-market trading following the announcement of a $100 million at-the-market equity program with Cantor Fitzgerald, which may undermine investor confidence and complicate future fundraising efforts.
- Market Reaction: The drop in Cybin's stock price reflects investor concerns regarding the new financing plan, potentially impacting the company's capital operations and shareholder value moving forward.
- Industry Impact: Concurrently, other biotech firms like Corcept Therapeutics and NovaBay Pharmaceuticals also experienced stock declines, indicating a cautious sentiment across the biotech sector that could affect the overall fundraising environment.
- Investor Focus: The lukewarm market response to Cybin's financing initiative may prompt the company to reassess its capital structure and financing strategies to navigate current market challenges.
Continue Reading